Fred Hutchinson Cancer Research Center
The assay could be useful for identifying patients who are HER2-negative by conventional IHC but who are likely to benefit from newer anti-HER2 therapies.
Adaptive Biotechnologies Prepares to Launch T Cell-Based COVID-19 Test
Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.
Fred Hutch Establishes CLIA Lab Focused on Targeted Mass Spec Protein Assays
The facility, which plans to launch an MRM assay for HER2 as its initial test, is one of the few clinical labs to focus primarily on targeted protein mass spec.
The cell collection device already has FDA clearance, while the firm intends to conduct trials in support of a filing for marketing clearance of the assay.
Lucid Diagnostics, Fred Hutchinson Cancer Research Center Ink Esophageal Cancer Biomarker Deal
The PAVmed subsidiary will have the option to license the biomarkers for a year after the completion of a Phase II study evaluating their accuracy.